Sumitomo Mitsui Ds Asset Management Company, LTD Nektar Therapeutics Transaction History

Sumitomo Mitsui Ds Asset Management Company, LTD

$9.15 Billion
Q3 2024

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2019 Oct 16, 2019	SELL	$16.91 - $36.27 $149,298 - $320,227	-8,829 Closed	0 $0
Q2 2019 Aug 13, 2019	SELL	$31.0 - $36.3 $76,694 - $89,806	-2,474 Reduced 21.89%	8,829 $314,000
Q1 2019 May 07, 2019	BUY	$31.58 - $46.35 $3,821 - $5,608	121 Added 1.08%	11,303 $379,000
Q2 2018 Jul 31, 2018	BUY	$46.25 - $104.45 $517,167 - $1.17 Million	11,182 New	11,182 $546,000

Others Institutions Holding NKTR

# of Institutions

146

Shares Held

139M

Call Options Held

32.6K

Put Options Held

14.1K

Deep Track Capital, LP Greenwich, CT

15.9M
Shares

$16.2 Million
0.76% of portfolio
Black Rock Inc. New York, NY

15.2M
Shares

$15.5 Million
0.0% of portfolio
Vanguard Group Inc Valley Forge, PA

13.1M
Shares

$13.4 Million
0.0% of portfolio
Eventide Asset Management, LLC Boston, MA

9.4M
Shares

$9.59 Million
0.22% of portfolio
Samlyn Capital, LLC New York, NY

9.2M
Shares

$9.38 Million
0.19% of portfolio

View Full List

About NEKTAR THERAPEUTICS

Ticker NKTR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 187,404,992
Market Cap $191M
Description
Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in areas of unmet medical need in the United States and internationally. The company's products include Bempegaldesleukin, a CD122-preferential interleukin-2 (IL-2) pathway agonist, which is in phase 3 clinical trial to treat metastatic melanoma, re...

More about NKTR

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Sumitomo Mitsui Ds Asset Management Company, LTD, based on Form 13F filings with the SEC.

News

Stay updated on Sumitomo Mitsui Ds Asset Management Company, LTD with notifications on news.

Account